Business
Suda Pharmaceuticals share price soars 200% on TGA approval – Motley Fool Australia
The Suda Pharmaceuticals share price is soaring over 200% following TGA approval for its insomnia treatment product, ZolpiMist.
The Suda Pharmaceuticals Ltd(ASX: SUD) share price has soared 207.4% today, at the time of writing. The surge came following the company’s announcement that its Zolpimist product has been approved by the TGA (Therapeutic Goods Administration). ZolpiMist is an oral spray for the treatment of insomnia.
In an investor presentation released by Suda Pharmaceuticals earlier this month, the company estimated the market for insomnia treatments will be approximately US$4 billion by 2026. Furthermore, a…
-
Business21 hours ago2 strong ASX ETFs to buy and hold forever
-
Business21 hours agoTop broker gives its verdict on Coles shares after 25% rise
-
Noosa News21 hours agoAndrew Burow: Link to alleged attacker uncovered in suspected murder of Kelvin Grove father
-
Business22 hours agoIs Nvidia’s increasing reliance on “Customer A” and “Customer B” a red flag for the AI growth stock?